Skip to main content

Table 3 Toxicities of patients treated with doxorubicin and olaratumab in our study, phase II and phase III ANNOUNCE study

From: Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland

Grade ≥ 3 adverse events2019 study (n = 172) (%)Phase II ANNOUNCE (n = 64) (%)Phase III ANNOUNCE (n = XX) (%)
All Grade  3 AEs82 (47.7%)51 (79.7%)Unknown
Anaemia21 (12.2%)8 (12.5%)Unknown
Neutropaenia57 (33.1%)34 (53.2%)48%
Neutropaenic fever7 (4.1%)8 (12.5%)Unknown
Thrombocytopaenia3 (1.7%)Unknown6%
Hepatotoxicity2 (1.2%)UnknownUnknown
Oral mucositis6 (3.5%)2 (3.1%)3%
Diarrhoea3 (1.7%)2 (3.1%)3%
Nausea2 (1.2%)1 (1.6%)2%
Vomiting3 (1.7%)0 (0%)0%
Fatigue3 (1.7%)6 (9.4%)9%
Cardiac toxicity6 (3.5%)a1 (1.6%)Unknown
Sepsis13 (7.6%)5 (7.8%)Unknown
  1. aOne patient (0.6%) had a myocardial infarction whilst on treatment